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ABSTRACT 
 
Progress in advancing a system-level understanding of the complexity of human tissue development 
and regeneration is hampered by a lack of biological model systems that recapitulate key aspects of 
these processes in a physiological context. Hence, growing demand by cell biologists for organ-
specific extracellular mimics has led to the development of a plethora of three-dimensional (3D) 
cell culture assays based on natural and synthetic matrices. We developed a physiological 
microenvironment of semi-synthetic origin, called gelatin-methacryloyl (GelMA)-based hydrogels, 
which combine the biocompatibility of natural matrices with the reproducibility, stability, and 
modularity of synthetic biomaterials. We describe here a step-by-step protocol for the preparation 
of the GelMA polymer, which takes 1–2 weeks to complete, and can be used to prepare hydrogel-
based 3D cell culture models for cancer and stem cell research, and tissue engineering. We also 
describe quality control and validation procedures, including how to assess the degree of GelMA 
functionalization, plus mechanical and diffusive properties, to ensure reproducibility in 
experimental and animal studies. 
 
INTRODUCTION 
 
In multicellular organisms, cells are embedded in a pericellular and/or an extracellular matrix 
(ECM). Structurally, the ECM of native tissues is subdivided into two general types: filamentous 
protein networks, as found in connective tissues1, and thin layers with sheet-like organization, 
which are found in basement membranes2. It is now thought that the ECM represents more than just 
a structural architecture that provides adhesion sites for cell surface receptors3. ECM homeostasis is 
a critical factor in preserving normal tissue function and tissue-specific mechanical and biochemical 
properties4. The interaction between cells and the surrounding ECM regulates a variety of 
physiological cellular processes, including motility, migration, invasion, and proliferation5,6. On the 
other hand, the crosstalk of cells with the local microenvironment promotes the development and 
progression of various diseases, including cancer7-9. 
The physico-chemical properties of the cellular microenvironment directly influence the state of 
differentiation of various cell types. For example, with regard to chondrocytes, the properties of the 
native or tissue-engineered ECM play a key role in the successful development of a functional 
cartilage matrix10-12. These effects of the extracellular microenvironment on cellular behavior are 
well-known; thus, experimental organ-specific model systems need to mimic physiological 
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conditions in humans, and their development has, therefore, become a major focus of biomedical 
research13-15. 
Two-dimensional (2D) cell culture systems, which are based on cells propagated as monolayers and 
are routinely utilized in research, differ greatly from the native microenvironment and often fail to 
adequately model normal tissue and disease processes16. To address this fundamental drawback of 
2D cell culture systems, tissue-engineered in vitro platforms have become the preferred model 
system for experimental organ-specific studies17. These platforms can rely on different 
technologies, so that they consist of a three-dimensional (3D) modular culture system, rather than a 
stand-alone model. These modular systems can, therefore, enable researchers to adequately 
engineer complex tissue-specific niches. Several 3D culture approaches based on natural, synthetic 
and semi-synthetic biomaterials are available to serve as physiologically relevant mimics of the 
ECM for cell biology, tissue engineering, and regenerative medicine applications18. Most of these 
3D cell culture systems consist of hydrogels, which are highly hydrated matrices of crosslinked 
polymer chains that mimic the 3D networks observed in native connective tissues19,20. 
 
Current 3D cell culture systems 
A wide variety of natural, synthetic, and semi-synthetic hydrogels have been successfully used as 
3D cell culture systems that mimic the extracellular microenvironment during disease development 
and progression21,22 or that provide a cell delivery vehicle for animal experiments23. Biomaterials 
utilized for these purposes include natural hydrogel-forming proteins, like collagen type I24, and 
more complex mixtures based on reconstructed basement membrane proteins, such as Matrigel25, as 
well as synthetic polymers, like polyethylene glycol13,23. Although collagen type I gels effectively 
recapitulate the properties of connective tissues and Matrigel enables researchers to conduct cell 
growth and differentiation studies17, such hydrogels derived from natural proteins often lack 
consistent properties and contain impurities resulting in high batch-to-batch variations16. Hence, 
researchers in the field of materials science have developed an array of synthetic hydrogels that are 
widely explored as 3D ECM mimics26. Although these synthetic polymers have the advantage of 
reproducible, well-defined, and tunable physico-chemical properties, they lack the cell-binding and 
protease cleavage motifs that are naturally found in ECM. This limitation can be overcome by 
adding cell-responsive sites, such as integrin cell-binding motifs, to synthetic polymers, thus 
engineering biomimetic materials27. 
Interestingly, other 3D cell culture approaches utilize scaffolds instead of hydrogels. For example, 
the work by the Cukierman group introduced cell-derived matrices as 3D culture and assay system 
that have the characteristics of basement membrane-like substrates in order to analyze cell 
morphology and behavior28. To create a specific type of basement membrane, the Lengyel team 
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developed an in vivo-like tumor microenvironment by layering mesothelial cells onto an omental 
basement membrane. This omental basement membrane is generated by mixing ECM proteins, 
including collagen type I, with primary fibroblasts to study ovarian cancer cell functions during 
metastasis29. Such a 3D culture approach for ovarian cancer represents an organotypic model that 
can be further expanded with other tissue-specific cell types present in the tumor microenvironment 
and enables the high-throughput screening of novel therapeutics30. Other approaches include the 
combined silk–collagen scaffolds developed by the Kaplan group to build a brain-like tissue, in 
which the biphasic architecture enables the spatially controlled growth of a neuronal network, thus 
mimicking the 3D morphology of the brain cortex31. Other scaffold technology platforms enable 
researchers to monitor oxygen levels and determine hypoxia in a 3D cell culture set-up32 and to 
investigate mechanisms that are altered during bone metastasis in patients with prostate cancer33. 
 
Gelatin-methacryloyl-based hydrogels as cell culture platforms that mimic ECM 
Our 3D cell culture technology platform, as described here, focuses on a semi-synthetic biomaterial 
that integrates the advantages of the aforementioned hydrogel types by harboring both integrin cell-
binding and protease cleavage sites, as well as chemically active substituents that ensure that the 
biomaterial has reproducible and tunable properties. These properties in combination enable cell 
adhesion and proteolytic degradation to take place and afford the ability to control the mechanical 
and biochemical characteristics of the hydrogels. Using gelatin-methacryloyl (GelMA)-based 
hydrogels, we established a 3D ECM mimic that can be used to conduct a wide range of 
experimental and animal studies, as well as to implement quantitative cell biology applications. 
Here, we describe a step-by-step protocol for the production of GelMA and the preparation of cell-
laden hydrogels that can be utilized as 3D culture systems for cancer and stem cell research, as well 
as for tissue engineering applications. We also describe validation protocols to characterize the 
degree of GelMA functionalization and the mechanical properties of differently crosslinked 
hydrogels, which are key factors in influencing the behavior of encapsulated cells. Finally, we 
demonstrate various applications for cell biological assays, including visualization of cell 
morphology, detection of cell viability and proliferation, as well as total RNA extraction. We also 
demonstrate the use of these hydrogels as cell delivery vehicles for different animal studies and as 
cardiomyocyte microchannel approach. 
 
Development of the protocol 
GelMA is prepared from gelatin, a soluble polypeptide mixture of denatured and partially 
hydrolyzed collagens derived from animal tissues, like skin, tendons, and bones34. The main 
component of gelatin is collagen type I34. Depending on the hydrolysis processing conditions and 
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tissue sources, a variety of gelatin products exist, which have slightly different compositions. 
According to our unpublished qualitative proteomic analysis, gelatin and GelMA mainly contain 
collagen types I and III, but they also contain traces of other collagen types. Although this approach 
is not covered in this protocol, collagen type IV (and its methacryloyl-substituted derivative) can be 
added to GelMA-based hydrogels with control over the collagen concentration, enabling 
researchers to implement a variety of cell-specific applications. 
Pure gelatin is water-soluble and forms thermo-reversible transparent hydrogels via physical 
interactions between collagen molecules35. However, this type of physical hydrogel is not stable at 
body temperature and does not allow researchers to control and fine-tune its properties. To obviate 
these drawbacks, gelatin has been chemically functionalized with unsaturated methacryloyl groups 
to result in GelMA, which forms covalently crosslinked hydrogels by photo-initiated 
polymerization under mild conditions35,36 and enables cell encapsulation with high viability10,37. 
Recent data from our research group suggest that GelMA prepared following the protocol described 
herein contains a mixture of methacrylamide and methacrylate groups, although the 
methacrylamide groups are the majority (> 90% of all the methacryloyl groups present in the 
hydrogel)38. As a result, terms that were widely used to describe this material in literature, such as 
gelatin methacrylamide, gelatin methacrylate or methacrylated gelatin, are not chemically accurate. 
Instead, we suggest using the term ‘gelatin methacryloyl’ to reflect the coexistence of both 
methacrylamide and methacrylate groups in GelMA38. 
The mechanical properties of GelMA-based hydrogels are readily tunable by varying the degree of 
methacryloyl substitution, polymer and photo-initiator concentrations, as well as photo-crosslinking 
time35,39. Specific physical or otherwise hydrogel characteristics are discussed in the Experimental 
design. The quantitative links between these factors and the predictable mechanical characteristics 
of the resulting hydrogels10,37 are taken into consideration in our detailed relevant validation 
procedure. This protocol demonstrates a user-friendly and highly reproducible procedure to prepare 
GelMA-based hydrogels using a custom-made Teflon casting mould, which enables matrices with 
reproducible biochemical compositions, sizes, and mechanical properties to be obtained. The 
resulting hydrogels are suitable for different biological assays and as cell delivery vehicles (Figure 
1). In addition, we describe how the covalent incorporation of methacryloyl-functionalized ECM 
components, such as hyaluronic acid methacrylate, yields complex ECM-mimicking matrices that 
can be adapted to act as tissue-specific model systems. 
 
Applications 
Our group’s modular tissue culture technology platform system is of prime interest, not only to 
biomedical engineers and biomaterial scientists, but also to cell and molecular biologists working 
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on applying novel biomaterial-based technology platforms to cancer research, and more generally in 
vitro disease models, as well as tissue engineering and regenerative medicine. We have 
demonstrated that GelMA-based hydrogels prepared following our protocol (Figure 2) can serve as 
3D model systems for studies on ovarian (Figure 3), breast (Figure 4), and prostate cancer33, and for 
cartilage tissue engineering applications10. In expanding the applicability of the GelMA tool box, 
we developed different hydrogel formulations to generate hybrid hydrogels with varying chemical, 
biological, mechanical, and electrical properties that enable the differentiation of stem cells to 
desired cell types and the formation of vascular networks (Figure 5)40. Integration of microchannels 
into these hydrogels can further stimulate vascular network formation41. Moreover, GelMA-based 
hydrogels have been used as an injectable gene delivery system to stimulate vasculogenesis for 
myocardial therapy42. 
In the context of cancer research, cell–ECM interactions mediate critical steps in cancer progression 
and drug responses18. GelMA-based hydrogels were successfully used to develop a 3D cell culture 
model that allows formation of multicellular spheroids from single ovarian cancer cells, the 
initiating process during peritoneal metastasis37. Variation of hydrogel stiffness resulted in changes 
of the cell morphology, metabolic activity, and proliferation rate37. Additionally, this spheroid-
based approach was applied to an ovarian cancer animal model (Figure 3). Cell-laden hydrogels 
were implanted intraperitoneally into NOD-scid mice. Tumor formation occurred 4 weeks post 
implantation, which enabled the administration and screening of a clinically used chemotherapeutic, 
paclitaxel, over 4 weeks. A paclitaxel response of 63% was detected (Figure 3), a value that is 
comparable to that determined in our previously published study using GelMA-based hydrogels37 as 
cell delivery vehicle of the same cell type in vivo. Similarly, metastatic breast cancer cells have 
been embedded within GelMA-based hydrogels and showed high cell viability over the duration of 
3D cell culture (Figure 4). These cell-laden hydrogels were then implanted in close proximity to a 
humanized tissue-engineered bone construct to mimic invasion of the humanized bone by the breast 
cancer cells (Figure 4). Hence, this method provides an approach to study breast cancer bone 
colonization in vivo43. 
In the context of tissue engineering and regenerative medicine, co-culture of human blood-derived 
endothelial colony-forming cells (ECFCs) and human bone marrow-derived mesenchymal stem 
cells (MSCs) encapsulated in GelMA-based hydrogels supported extensive formation of a 3D 
capillary-like vascular network in vitro (Figure 5). The co-culture of ECFCs and MSCs can be 
further expanded by co-culturing endothelial cells with pericytes or smooth muscle cells. 
Importantly, functional anastomoses between the newly formed vascular network in vitro and the 
native vasculature upon implantation into male athymic nude (nu/nu) mice were observed, 
indicating potential regenerative applications40. By combining microfluidic systems with GelMA-
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based hydrogels, GelMA prepolymers can be readily used to coat these microchannels. After photo-
crosslinking, the hydrogel coating layer stimulates functions like cell adhesion and alignment 
within the microchannels, suggesting that these hydrogels are uniquely qualified for organ-on-a-
chip applications, such as for cardiomyocyte cultures (Figure 6). Cardiomyocytes are elongated 
along the flow direction growing with cardiac fibers aligned inside the microchannels (Figure 6). 
This cardiomyocyte microchannel approach represents an in vitro model for diagnosis and drug 
screening applications, due to the widely known advantages of organ-on-a-chip models, including 
feasible control of the cellular microenvironment, delivery of nutrients and chemical cues to the 
cells through continuous medium perfusion, as well as reduction in the amount of reagents and cells 
during experiments44. 
Many studies described in the literature are stand-alone demonstrations of a specific biomaterial or 
a combination of different methods into a 3D model for a single application, but a modular 3D 
tissue culture technology platform is still lacking16. Our protocol covers the complete 
manufacturing process, including polymer functionalization, standardized preparation of 3D cell 
cultures, and the application and characterization of cell-laden hydrogels for cancer and stem cell 
research, as well as tissue engineering applications. This broad spectrum of biomedicine-based 
research provides the much-needed continuity that will enable researchers to cross-validate different 
applications, a feature desperately needed in the area of 3D ECM mimics26. 
 
Limitations 
GelMA-based hydrogels can cover a wide spectrum of physico-chemical properties by varying key 
parameters and factors in the hydrogel formulation, photo-crosslinking conditions, and 
incorporation of additional ECM components to generate a library of hydrogels. The protocol 
described herein thus serves as a basis for further optimisation, depending on the encapsulated cell 
type and targeted culture model. 
The surface properties of a wide variety of hydrogels commonly employed for 3D cell culture 
applications, including GelMA, are highly dependent on the properties of the substrate it is 
crosslinked on. Even for the same chemical structure, a hydrogel prepared on a hydrophobic 
substrate, such as Teflon, exhibits a lower crosslinking density at its surface than a hydrogel 
prepared on a hydrophilic substrate45. This effect has been largely neglected in the literature, yet it 
can be observed in a wide variety of hydrogels, including those commonly used for 3D cell culture 
applications, such as polyethylene glycol, and, to a far lesser extent, GelMA. Although the effects 
of the crosslinking substrate on the bulk hydrogel physico-chemical properties are negligible for 
thick constructs (e.g. 2 mm), thin GelMA-based hydrogels (e.g. 1 mm) prepared on Teflon show 
increased swelling and lower compressive moduli compared to thick constructs (Figure 7). As this 
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substrate effect only occurs at the immediate surface of the hydrogel, the bulk mechanical and 
swelling properties of thick hydrogel constructs remain unaffected by the properties of the 
substrate. Therefore, it is recommended using consistently a standardized protocol and identical 
experimental conditions to ensure reproducibility. 
Another limitation is the necessity to optimize the hydrogel composition to encapsulate more 
biologically sensitive cells, such as endothelial cells, with high viability. As described herein, these 
cell types require a low degree of GelMA functionalization and a low crosslinking density of the 
GelMA-based hydrogel to achieve physiological cell behavior. 
 
Experimental design 
A GelMA-based hydrogel experiment can be designed by combining some of, but not necessarily 
all, the procedures described below. GelMA functionalization, dialysis and lyophilization will need 
to be included in any experimental study (steps 1–11), as well as preparation of GelMA precursor 
solution and hydrogel construct preparation (with or without encapsulated cells, steps 14–26). 
Characterization of GelMA functionalization is highly recommended to perform on every newly 
synthesized and purified batch, to ensure the intended degree of methacryloyl-substitution has been 
obtained (steps 12–13). Mechanical testing is highly recommended as a functional quality control 
test to ensure agreement between batches and experiments (steps 27–36). In addition, mechanical 
testing can be an assessment of degradation or tissue formation studies. Microscopy imaging will be 
part of most 3D cell cultures (step 37), as well as the assessment of cell viability and proliferation 
(steps 38–39). Total RNA extraction from GelMA-based hydrogels can be performed when 
interested in the gene expression of encapsulated cells grown in 3D (steps 40–41). 
Hydrogel casting mould. Photo-polymerization of the GelMA precursor solution is performed in a 
casting mould made of Teflon (Polytetrafluoroethylene). In our laboratory, we use a mould to 
produce hydrogel strips with the dimensions of 50 mm x 4 mm x 2 mm (length x width x height), 
which are cut into smaller units of 4 mm x 4 mm x 2 mm (length x width x height) using custom 
acrylic cutting guides and a scalpel after photo-polymerization (Figures 1 and 2). Before 
commencing with the procedure outlined in this protocol, it is recommended manufacturing Teflon 
moulds and laser-cutting of cutting guides needed for the preparation of GelMA-based hydrogels as 
per technical drawings provided in the Supplementary Figures 1 and 2. Note that the design of both 
mould and cutting guides may be customized to produce hydrogels of different shapes and sizes, 
depending on your experimental needs. 
Tailoring mechanical properties of GelMA-based hydrogels. As indicated earlier, the 
mechanical properties of GelMA-based hydrogels can be tailored by variation of one or more of the 
following factors: the degree of functionalization (DoF), the polymer and photo-initiator 
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concentrations, as well as photo-crosslinking time. For example, the DoF directly influences the 
highest achievable crosslinking density of the hydrogel matrix, and ultimately the hydrogel porosity 
and mechanical properties. When other factors remain unchanged, increasing the DoF leads to 
stiffer hydrogels with a higher crosslinking density and improved shape fidelity39, while the pore 
size decreases40. Increasing the polymer concentration or photo-crosslinking time generally yields 
stiffer hydrogels39. These factors can be varied within a large range without affecting handling or 
compromising cell viability and function, but should be optimized for each cell type. Changes to the 
photo-initiator concentration will affect the crosslinking kinetics, and a shorter photo-crosslinking 
time may be required to yield hydrogels with comparable mechanical properties when the initiator 
concentration is increased. Increasing the photo-crosslinking time leads to a higher crosslinking 
density and stiffness, both of which plateau when the hydrogel is fully crosslinked. For a detailed 
description of how the above mentioned factors influence hydrogel properties, refer to our 
previously published work39. It is recommended using the parameters summarized in Table 1 as a 
basis for further optimization. 
Avoiding oxygen inhibition of photo-initiated polymerization. Oxygen is known to affect the 
photo-initiated polymerization of acrylate and acrylamide-based chemistries46. Thus, the degree of 
photo-crosslinking and mechanical properties of the hydrogels can be compromised by the influx of 
oxygen during hydrogel photo-polymerization. It is therefore necessary to remove existing air 
bubbles and cover the hydrogel precursor solution with a glass slide during UV-exposure/photo-
polymerization as outlined in the following protocol, as well as depicted in Figures 1 and 2. 
Degassing of the hydrogel precursor solution is not necessary. 
Photo-polymerization of GelMA-based hydrogels. UV-initiated crosslinking of cell-laden 
hydrogels is a commonly applied method, and, to our knowledge, no significant adverse effects on 
cell viability and function have been reported, despite its extensive use with diverse cell types, 
including primary cells. The damage UV light may cause is highly dependent on its wavelength and 
the nature of the radicals it creates. Since DNA has an absorption maximum of 260 nm, it is 
recommended using a wavelength of 365 nm to minimize the risk of direct DNA damage. Our most 
recent results suggest that radicals generated by UV exposure preferentially react with the 
unsaturated methacryloyl groups of GelMA, which therefore have a cell-protective effect47. As a 
result, cell viability and function are not compromised by UV-initiated crosslinking47. 
Co-polymerization of methacryloyl-substituted ECM components for tissue-specific models. 
To yield tissue-specific 3D models, methacryloyl substituted ECM components may be co-
polymerized with GelMA. For example, for human articular chondrocyte cultures, hyaluronic acid 
can be functionalized with methacrylate groups by reaction with methacrylic anhydride to yield 
hyaluronic acid methacrylate (HAMA) which enables the covalent and stable incorporation of 
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hyaluronic acid into the hydrogel matrix and was shown to enhance chondrogenic cell 
differentiation, accumulation of cartilaginous ECM, and mechanical properties in articular cartilage 
tissue engineering applications when compared to GelMA alone48. The GelMA concentrations 
recommended for in vitro chondrogenesis are within the physiological range of the collagen content 
of human articular cartilage. The mean (range) content of collagen type II in normal human 
articular cartilage is 14% (9.2–20.8%; weight per wet weight)49, which is very similar to the 10% 
typically used in our experiments48. While not specifically outlined in the following protocol, this 
principle can also be applied to other relevant ECM components to study their effects on cellular 
behavior. 
Mechanical testing of GelMA-based hydrogels. To perform unconfined compression tests (Figure 
7), in our laboratory, we are using a custom-manufactured immersion bath comprised of an 
aluminum block with a rectangular recess, which is capable of holding up to 25 ml of buffer for the 
mechanical testing of hydrogels. Beneath this recess, the aluminum block features a longitudinal 
feed-through with tubing attachments on either side, allowing perfusion with temperature-
controlled water using an aquarium water pump, tubing and a conventional laboratory water bath. 
 
MATERIALS 
 
Reagents 
! CAUTION When handling the chemicals used in this protocol, always wear suitable personal 
protective equipment, including a lab coat, nitrile gloves, safety goggles, and, where indicated, a 
face shield and respirator. For any chemical listed in this protocol, appropriate institutional and 
governmental safety guidelines must be followed. Please refer to the respective material safety data 
sheets. 
 
GelMA functionalization, dialysis and lyophilization 
 Gelatin from porcine skin, type A, gel strength 300 bloom (Sigma Aldrich, cat. no. G2500, 
store at room temperature (RT) at 23–25 °C) 
▲ CRITICAL Other types of gelatin can also be used to prepare GelMA following the 
same protocol, if necessary. This may, however, affect the properties of the materials and 
resulting hydrogels. 
 Methacrylic anhydride (Sigma Aldrich, cat. no. 276685, store at RT) 
! CAUTION Methacrylic anhydride is a volatile and toxic organic compound, which may 
cause skin irritation, serious eye damage, and respiratory irritation if inhaled. Always wear a 
face shield and respirator. Avoid any direct contact. 
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 Phosphate-buffered saline (PBS), pH 7.4 (Life Technologies, cat. no. 100100, store at RT) 
 NaHCO3 (Sigma Aldrich, cat. no. S6014, store at RT) 
 Irgacure® 2959 (IC2959; BASF, cat. no. 029891301PS04, store at RT) 
 Hyaluronic acid (Hyasis®; Novozymes, molecular weight 0.86 MDa, CAS no. 9067-32-7, 
store air-tight in a dry place at 4 °C) 
▲ CRITICAL If necessary, hyaluronic acid from other manufacturers can also be used. 
However, the source and molecular weight may influence cell behavior. 
 Liquid nitrogen 
! CAUTION Contact of liquid nitrogen with the skin or eyes may cause serious frostbite 
injury. When handling liquid nitrogen, always wear appropriate personal protective 
equipment, including a long sleeve lab coat, thermo-insulated gloves, safety goggles and a 
full face shield. 
 
Characterization of GelMA functionalization 
 Ninhydrin (Sigma-Aldrich, cat. no. 151173, store at RT) 
 Sodium citrate monobasic (Sigma-Aldrich, cat. no. 71498, store at RT) 
 HCl (Sigma-Aldrich, cat. no. 84435, store at RT) 
 Glycerol (Sigma-Aldrich, cat. no. G5516, store at RT) 
 UltraPure™ DNase/RNase-free distilled water (Life Technologies, cat. no. 10977-015, store 
at RT) 
 Fluoraldehyde™ o-phthaldialdehyde reagent solution (Life Technologies, cat. no. 26025, 
store at 4 °C) 
 
Human ovarian cancer cell culture 
 OV-MZ-6 cells13 or any other cell line of interest and the appropriate medium in which to 
culture these cells 
! CAUTION The cell lines used in your research should be regularly checked to ensure they 
are authentic and are not infected with mycoplasma. 
 DMEM, high glucose, no sodium pyruvate (Life Technologies, cat. no. 10566-016, store at 
4 °C) 
 HEPES (Life Technologies, cat. no. 15630-080, store at 4 °C) 
 Penicillin–Streptomycin, 10,000 U/ml (Life Technologies, cat. no. 15140-122, store at –
20 °C) 
 Gentamycin (Life Technologies, cat. no. 15710-064, store at 4 °C) 
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 Fetal bovine serum (FBS, Lonza, ca. no. 14-501F, store at –20 °C) 
▲ CRITICAL Always use the same batch of FBS for replicate experiments. 
 L-Arginine (Sigma-Aldrich, cat. no. A-5131, store at RT) 
 L-Asparagine (Sigma-Aldrich, cat. no. A-4159, store at RT) 
 Versene (Life Technologies, cat. no. 15040-066, store at 4 °C) 
 
Human chondrocyte culture 
 Human articular chondrocytes (see Reagent setup) 
! CAUTION Informed consent must be obtained for experiments involving human tissues 
and cells. Experiments must conform to all relevant institutional and governmental 
regulations. 
 DMEM, high glucose, sodium pyruvate, no glutamine (Life Technologies, cat. no. 10313-
021, store at 4 °C) 
 HEPES (see above) 
 Penicillin–Streptomycin (see above) 
 MEM non-essential amino acids solution, 100x (Life Technologies, cat. no. 11140-050, 
store at 4 °C) 
 GlutaMAX™ supplement (Life Technologies, cat. no. 35050-061, store at 4 °C) 
 L-Proline (Sigma-Aldrich, cat. no. P5607, store powder at RT, store solution at –20 °C) 
 L-Ascorbic acid (Sigma-Aldrich, cat. no. A92902, store powder at RT, store solution at –
20 °C) 
 Insulin-Transferrin-Selenium (ITS-G), 100x (Life Technologies, cat. no. 41400-045, store at 
4 °C) 
 Bovine serum albumin (BSA; Sigma-Aldrich, cat. no. A9418, store at 4 °C) 
 Human recombinant transforming growth factor beta 3 (TGF-β3; GroPep, cat. no. BJU100, 
store at 4 °C) 
 Dexamethasone (Sigma-Aldrich, cat. no. D4902, store powder at 4 °C, store solution at –
80 °C) 
 Trypsin (Life Technologies, cat. no. 15090-046, store at 4 °C) 
 
Co-culture of human ECFCs and MSCs for vascular network formation 
 Human ECFCs (see Reagent setup) 
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! CAUTION Informed consent must be obtained for experiments involving human tissues 
and cells. Experiments must conform to all relevant institutional and governmental 
regulations. 
 Human MSCs (see Reagent setup) 
! CAUTION Informed consent must be obtained for experiments involving human tissues 
and cells. Experiments must conform to all relevant institutional and governmental 
regulations. 
 Endothelial basal medium (EBM-2; Lonza, cat. no. CC-3156, store at 4 °C) 
 SingleQuots (Lonza, cat. no. CC-4176, store at 4 °C) 
 MSC growth medium (MSCGM; Lonza, cat. no. PT-3238, store at 4 °C) 
 HEPES (see above) 
 Penicillin/Streptomycin (see above) 
 GlutaMAX™ supplement (see above) 
 FBS (see above) 
 Basic fibroblast growth factor (bFGF; R&D System, cat. no. 4826/10, store at 4 °C) 
 
Confocal laser scanning confocal microscopy (CLSM) 
 Fluorescein diacetate (FDA; Life Technologies, cat. no. F1303, store powder at 4 °C, store 
solution at –20 °C) 
 Propidium iodide (PI; Life Technologies, cat. no. P3566, store at 4 °C) 
 Triton™ X-100 (Sigma-Aldrich, cat. no. X100, store at RT) 
 Glycine (Sigma-Aldrich, cat. no. G8898, store powder at RT, store solution at 4 °C) 
 Paraformaldehyde (PFA; Sigma-Aldrich, cat. No. 158127, store powder at 4 °C, store 
solution at –20 °C) 
! CAUTION PFA is a potent fixative and hazardous. Avoid any direct contact and wear 
appropriate personal protective equipment. 
 Rhodamine 415–conjugated phalloidin (Life Technologies, cat. no. R415, store at –20 °C) 
! CAUTION Rhodamine 415–conjugated phalloidin is toxic and harmful. Avoid any direct 
contact and wear appropriate personal protective equipment. 
 4´,6-diamidino-2-phenylindole (DAPI; Life Technologies, cat. no. D1306, store powder at 
RT, store solution at –20 °C) 
 
Cell viability and proliferation assays 
 AlamarBlue® cell viability reagent (Life Technologies, cat. no. DAL1025, store at 4 °C) 
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 CyQuant® cell proliferation assay kit (Life Technologies, cat. no. C7026, store at –20 °C) 
 Proteinase K (Life Technologies, cat. no. 25530-015, store at 4 °C) 
 Na2HPO4 (Merck Chemicals, cat. no. 106586, store at RT) 
 NaH2PO4 x H2O (Merck Chemicals; cat. no. 106342, store at RT) 
 Na2EDTA (Ajax Finechem, cat. no. 180-500G, store at RT) 
 NaCl (Merck Chemicals, cat. no. 106406, store at RT) 
 EDTA (Merck Chemicals, cat. no. 108418, store at RT) 
 RNase A (Life Technologies, cat. no. 12091-021, store at RT) 
 UltraPure™ DNase/RNase-free distilled water (see above) 
 
Total RNA extraction from GelMA-based hydrogels 
 TRIzol® Reagent (Life Technologies, cat. no. 15596-026, store at 4 °C) 
! CAUTION TRIzol® Reagent contains phenol (toxic and corrosive) and guanidine 
isothiocyanate (an irritant), and may be hazardous if not handled properly. Follow the 
manufacturer’s instructions and always work in a chemical safety fume hood and wear 
appropriate personal protective equipment. 
 RNaseZap® RNase decontamination solution (Life Technologies, cat. no. AM9780, store at 
RT) 
 Chloroform (Sigma-Aldrich, cat. no. C2432, store at RT) 
 2-Propanol (Sigma-Aldrich, cat. no. I9516, store at RT) 
 Ethanol, 200 proof (Sigma-Aldrich, cat. no. E7023, store at RT) 
 UltraPure™ DNase/RNase-free distilled water (see above) 
 RNeasy Micro Kit, including RLT buffer (Qiagen, cat. no. 74004, store at RT and 4 °C) 
 Borosilicate beads, 3 mm diameter (Sigma-Aldrich, cat. No. Z143928, store at RT) or 
stainless steel beads, 5 mm diameter (Qiagen, cat. No. 69989, store at RT) 
 β-mercaptoethanol (Sigma-Aldrich, cat. No. M3148, store at RT) 
! CAUTION β-mercaptoethanol is a hazardous and toxic. Follow the manufacturer’s 
instructions, work in a chemical safety fume hood and wear appropriate personal protective 
equipment. 
 Agarose, low electroendosmosis (Sigma-Aldrich, cat. no. 11685678001, store at RT) 
 
EQUIPMENT 
 
GelMA functionalization, dialysis and lyophilization 
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 Round bottom flask with magnetic stir bar 
▲ CRITICAL Use a stir bar of sufficient size with a powerful stirrer to ensure good 
dispersion of methacrylic anhydride. Alternatively, an overhead stirrer with propeller 
agitator can be used instead of a magnetic stir bar. 
 Freeze-dryer 
 Sterile 50-ml centrifuge tubes with vented caps (0.2 µm pore size), for example Corning® 
50-ml Mini Bioreactor (Sigma-Aldrich, cat. no. CLS431720) 
 Sterile syringes (50-ml volume) 
 Syringe filter units or disposable vacuum filtration units with polyethersulfone (PES) 
membrane (0.2 µm pore size), for example Nalgene™ Rapid-Flow™ sterile disposable 
filters (Thermo Scientific, cat. no. 595-3320) 
 Dialysis membrane with a 12 kDa molecular weight cut-off 
 CL-1000 UV crosslinker (UVP; Upland California; or similar) with 365 nm wavelength 
tubes 
▲ CRITICAL Ensure a UV intensity of 2.2–2.8 mW/cm2 in the crosslinker center. The 
intensity will vary throughout the crosslinker, with intensities in the corners only half as 
high as that in the center. 
 Teflon casting mould (see Supplementary Figure 1) 
▲ CRITICAL Clean Teflon mould with warm water and sterilize with 70% (vol/vol) 
ethanol before usage; autoclaving may damage the mould. 
 Un-treated microscope glass slides 
▲ CRITICAL Ensure usage of the same brand or type of glass slides to exclude variation 
of hydrogel properties due to different light permeation through different glass slides. 
 Hydrogel cutting guides, laser-cut poly(methyl methacrylate; see Supplementary Figure 2) 
▲ CRITICAL Do not autoclave; clean with warm water and sterilize with 70% (vol/vol) 
ethanol before usage. Distance of individual cuts of cutting guides can be modified to allow 
hydrogel preparation of certain length. 
 Scalpel holders 
 Scalpel blades (size 11 or 22) 
 
Mechanical testing of GelMA-based hydrogels 
 Instron MicroTester 5848 (Instron), or similar mechanical tester, with a 5 N-load cell 
 Temperature-controlled water bath 
 Fluidic chamber (hydrogel immersion bath) 
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 Aquarium water pump 
 
Brightfield microscopy and CLSM 
 Eclipse (Nikon) or similar fluorescence microscope 
 SP5 (Leica) or similar confocal microscope 
 
Cell viability and proliferation assays 
 Black 96-well plates for fluorescence measurements 
 POLARStar OPTIMA plate reader (BMG, Labtech) or similar fluorescent plate reader; 
wavelength measurements of fluorescent signals: excitation 544 nm, emission 590 nm 
(AlamarBlue® assay), excitation 485 nm, emission 520 nm (CyQuant® assay) 
 
Total RNA extraction from GelMA-based hydrogels 
 DNase/RNase-free, 2-ml conical microcentrifuge tubes 
 Standard laboratory bench top centrifuge for 2-ml conical microcentrifuge tubes 
 Nanodrop-ND-1000 photo-spectrometer 
 Bullet Blender tissue homogenizer (Next Advance), Mini-Beadbeater (BioSpec Products), 
TissueLyser LT (Qiagen) or a similar mechanical tissue homogenizer 
 Bioanalyzer (Agilent Technologies)  
 
Other laboratory equipment 
 Cell culture incubator 
 Sterile 24-well and 48-well plates for 3D cell culture 
 Opaque 96-well plates for photo-spectroscopy 
 Photo-spectrometer (plate reader) 
 Hemocytometer or cell counter 
 Positive-displacement pipette and sterile capillary piston tips (1-ml nominal volume) 
 Water bath 
 Heat block 
 Shaker/rocker plate 
 Sterile 1.5-ml, 2-ml, 15-ml, and 50-ml conical (micro)centrifuge tubes 
 200–500-ml glass beaker 
 Spatula 
 Forceps 
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REAGENT SETUP 
 
▲ CRITICAL Culture cells on tissue culture plastic to ~ 80% confluency in suitable culture 
medium (see below) before encapsulation in GelMA-based hydrogels. 
 
Medium for human ovarian cancer OV-MZ-6 cell culture. Prepare high glucose (4.5 g/l) 
DMEM supplemented with 10 mM HEPES, 50 U/ml penicillin, 50 μg/ml streptomycin, 20 μg/ml 
gentamycin, 10% (vol/vol) FBS, 0.550 mM L-Arginine, and 0.272 mM L-Asparagine. This medium 
can be stored at 4 °C for 4–6 weeks. 
 
Human articular chondrocytes. Isolate these cells from the full-thickness cartilage of patients 
undergoing total knee replacement surgery for osteoarthritis as described elsewhere10. Cells 
encapsulated in GelMA-based hydrogels are cultured in high glucose (4.5 g/l) DMEM 
supplemented with 10 mM HEPES, 50 U/ml penicillin, 50 μg/ml streptomycin, 0.1 mM MEM non-
essential amino acids, 2 mM GlutaMAX™, 0.4 mM L-Proline, freshly added at each medium 
change, 0.1 mM L-Ascorbic acid, ITS-G (1:100), 1.25 mg/ml BSA, 10 ng/ml TGF-β3, and 0.1 μM 
dexamethasone. This medium can be stored at 4 °C for 4–6 weeks. 
 
Human ECFCs. Isolate these cells from the mononuclear cell fraction of human cord blood 
samples as described elsewhere40. Cells are expanded in EBM-2 supplemented with SingleQuots, 
50 U/ml penicillin, 50 μg/ml streptomycin, 2 mM GlutaMAX™, and 20% (vol/vol) FBS. This 
medium can be stored at 4 °C for 4–6 weeks. 
 
Human MSCs. Isolate these cells from the mononuclear cell fraction of human bone marrow 
samples as described elsewhere40. Cells are expanded in MSCGM supplemented with 50 U/ml 
penicillin, 50 μg/ml streptomycin, 2 mM GlutaMAX™, 10% (vol/vol) FBS, and 10 ng/ml bFGF. 
This medium can be stored at 4 °C for 4–6 weeks. 
 
Sodium citrate buffer for ninhydrin assay. Prepare a sodium citrate monobasic 0.5 M solution in 
demineralized or ultrapure water (107 mg/ml) and adjust to pH 5.5 using HCl 1.0 M. Prepare the 
solution as required and store according to the manufacturer’s instructions. 
 
Solutions for CLSM. Prepare a 10 mg/ml stock solution of FDA in PBS by dissolving 1 g of FDA 
in 1 ml of PBS and store protected from light at –20 °C (can be stored for at least 1 year). Prepare a 
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4% (wt/vol) solution of PFA dissolved in PBS and store at –20 °C (can be stored for at least 1 year). 
Prepare a glycine 0.1 M solution in PBS and store at 4 °C (can be stored for 1–2 months). Prepare a 
1% (wt/vol) solution of BSA in PBS by dissolving 1 g of BSA in 100 ml of PBS and store at 4 °C 
(can be stored for 1–2 months). Prepare a 5 mg/ml stock solution of DAPI in PBS by dissolving 
10 mg of DAPI in 2 ml of PBS and store protected from light at –20 °C (can be stored for at least 
1 year). It is recommended that the following solutions are sterile-filtered using 0.2-μm syringe 
filter units prior to usage: 4% (wt/vol) PFA, glycine 0.1 M solution, and 1% (wt/vol) BSA in PBS. 
 
Solutions required for CyQuant® assay. Prepare phosphate-buffered EDTA (PBE) buffer 
containing 20 mM Na2HPO4, 30 mM NaH2PO4 x H2O and 5 mM Na2EDTA in 500 ml of 
demineralized or ultrapure water; adjust pH to 7.1 and autoclave at 121 °C for 15 min. Make a stock 
solution of 100 mg of proteinase K in 10 ml of PBE buffer and prepare a fresh final concentration 
of 0.5 mg/ml of proteinase K in PBE buffer. Prepare 5 ml of RNase A solution per 96-well plate 
(180 mM NaCl, 1 mM EDTA, 4.5 ml of ultrapure™ DNase/RNase-free distilled water, 0.5 ml of 
20x CyQuant® lysis buffer and 1.4 U/ml RNase A stock). Prepare 10  ml of CyQyant® GR dye 
solution per 96-well plate (9.5 ml of ultrapure™ DNase/RNase-free distilled water, 0.5 ml of 20x 
CyQuant® lysis buffer and 50 µL of CyQyant® GR dye stock). Prepare the solutions as required and 
store according to the manufacturers’ instructions. 
 
PROCEDURE 
 
GelMA functionalization, dialysis and lyophilization  TIMING 1–2 weeks 
! CAUTION Perform GelMA functionalization in a chemical safety fume hood and wear 
appropriate personal protective equipment, including a lab coat, nitrile gloves and safety goggles. 
▲ CRITICAL Ensure cleanliness of all glassware and laboratory equipment to avoid chemical 
contamination during GelMA functionalization and purification steps. 
▲ CRITICAL GelMA is light-sensitive; maintain lyophilized GelMA and solutions containing 
GelMA in the dark, for example by wrapping the dialysis setup and conical centrifuge tubes in 
aluminum foil. 
▲ CRITICAL Maintain the GelMA solution at 37–50 °C to avoid thermal gelation between the 
functionalization and purification steps, for example in a water bath or oven. 
1| Soak gelatin to a final concentration of 10% (wt/vol) in demineralized or ultrapure water (or 
PBS) at RT in a round bottom flask with a magnetic stir bar. Stir the resulting mixture moderately 
for 10–60 min to facilitate gelatin dissolution. For a large reaction volume, an overhead stirrer 
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should be used instead of a magnetic stir bar. In our laboratory, we have tested reaction volumes of 
up to 300 ml, corresponding to 30 g of gelatin35. 
2| While moderately stirring, heat the mixture to (and keep at) 50 °C in a water bath until the 
gelatin is fully dissolved and the solution becomes clear. 
3| While stirring vigorously, slowly add 0.6 g of methacrylic anhydride (very viscous liquid) 
per 1 g of dissolved gelatin for a high degree of methacryloyl-functionalization. Continue stirring 
vigorously for 60 min. If mixing is sufficient, the solution will turn homogeneously opaque due to 
dispersion of methacrylic anhydride. Alternatively, this reaction can be run for up to 3 h; however, 
the reaction time and temperature, as well as the mass ratio of methacrylic anhydride to gelatin are 
used determine the degree of GelMA functionalization. 
▲ CRITICAL STEP Ensure adequate stirring during GelMA functionalization while minimizing 
air uptake. Insufficient stirring will lead to visible phase separation. 
▲ CRITICAL STEP Use a glass pipette when handling the methacrylic anhydride as organic 
solvents may dissolve plastic pipette tips. 
▲ CRITICAL STEP DoF can be varied by changing the ratio of methacrylic anhydride to gelatin. 
Use 0.6 g of methacrylic anhydride per 1 g of gelatin for a high DoF (75 ± 9% DoF39 as assessed 
using a ninhydrin assay or fluoraldehyde assay, step 13), or 0.06 g of methacrylic anhydride per 1 g 
of gelatin for a low DoF (31 ± 7% DoF as assessed using a ninhydrin assay, step 13). Ultimately, 
the DoF will influence the crosslinking density, and hence, porosity and mechanical properties of 
hydrogel constructs and needs to be chosen based on the cell type used (see Experimental design 
and Table 1). 
? TROUBLESHOOTING 
4| After the reaction period, transfer the solution into 50-ml tubes and remove unreacted 
methacrylic anhydride by centrifugation at 3,500 g for 3 min at RT. Decant the GelMA-containing 
supernatant (clearly visible and separated from the ‘pellet) into a large (200–500-ml) glass beaker 
and discard the unreacted methacrylic anhydride deposited at the bottom of the 50-ml tubes (opaque 
and viscous ‘pellet’). 
? TROUBLESHOOTING 
5| Dilute the supernatant solution with two volumes of pre-heated (40 °C), demineralized or 
ultrapure water. 
6| Transfer the solution to a dialysis membrane with a 12 kDa molecular weight cut-off and 
dialyze at 40 °C against a large volume of demineralized or ultrapure water for 5–7 days in a 
chemical safety fume hood. Change water at least once daily. Alternatively, dialysis can be 
performed at 4 °C in the cold room to minimize degradation. However, this may require extended 
dialysis time due to reduced diffusion at lower temperatures. 
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▲ CRITICAL STEP Methacrylic anhydride and acid byproduct are cytotoxic and may influence 
viability of encapsulated cells. It is therefore critical to fully remove these contaminants by dialysis 
before proceeding to step 7. Dialysis is completed when the GelMA solution appears clear, and the 
odor of residual methacrylic anhydride or methacrylic acid byproduct is no longer noticeable. 
? TROUBLESHOOTING 
7| Adjust the pH of the GelMA solution to 7.4 using NaHCO3 1 M. 
? TROUBLESHOOTING 
8| In a class II biological safety cabinet, sterile-filter the GelMA solution using 0.2-μm syringe 
filter units or disposable vacuum filtration units with a PES membrane. 
▲ CRITICAL STEP Treat GelMA and GelMA solutions as sterile after this step. 
? TROUBLESHOOTING 
9| Aliquot the GelMA solution into 50-ml tubes and snap-freeze them in liquid nitrogen. 
     PAUSE POINT Samples can be stored at –80 °C for at least 1 month. 
10| Transfer all aliquots to the freeze-dryer without allowing the solutions to thaw, and 
lyophilize until GelMA is fully dehydrated (typically 4–7 days). To maintain a sterile barrier during 
lyophilization, the 50-ml tubes need to be sealed with vented screw-top caps or press-fitted with 
0.2-μm syringe filter units prior to lyophilization. Exchange vented caps or filters with standard 
screw-top caps after lyophilization is completed to avoid hygroscopic absorption of water during 
storage specified in step 11. 
11| Store lyophilized GelMA protected from light and moisture at –20 °C until usage. 
     PAUSE POINT Lyophilized GelMA can be stored safely in the mentioned conditions for at 
least 1 year. 
 
Characterization of GelMA functionalization  TIMING 1–2 h 
▲ CRITICAL We recommend that steps 12 and 13 should be performed each time a new batch of 
GelMA is made. 
12| Soak duplicate samples of GelMA and gelatin at 3.5 mg/ml in ultrapure water. Although 
only ~ 0.2 mg are needed, weigh in at least ~ 10 mg of these duplicate samples for increased 
accuracy. 
13| Determine the DoF of GelMA implementing the ninhydrin assay (option A), or the 
fluoraldehyde assay (option B). Both options are equally valid. 
 
(A) Ninhydrin assay to determine the DoF 
(i) Prepare a mixture of one part sodium citrate monobasic 0.5 M and two parts of glycerol, for 
example 1 ml of sodium citrate monobasic (0.5 M) and 2 ml of glycerol. 
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(ii) Heat GelMA samples from step 12 to 50 °C and mix until the solution becomes 
homogenous and transparent. 
(iii) For gelatin solutions, prepare 50% (0.5 ml of gelatin solution and 0.5 ml of ultrapure water), 
20% (0.2 ml of gelatin solution and 0.8 ml of ultrapure water) and 10% (0.1 ml of gelatin solution 
and 0.9 ml of ultrapure water) dilutions to obtain the standard curve. 
(iv) Dissolve ninhydrin in the sodium citrate monobasic/glycerol mixture prepared in step 13A 
(i) to a final ninhydrin concentration of 2.5 mg/ml. 
(v) Prepare 2-ml tubes containing 0.950 ml of the ninhydrin solution prepared in step 13A (iv). 
(vi) Heat a water bath to 50 °C. 
(vii) Transfer 50 µl aliquots of the GelMA and gelatin solutions prepared in steps 13A (ii) and 
13A (iii), respectively into the tubes containing ninhydrin solution prepared in step 13A (v) and 
include two blanks (50 µl of ultrapure water). 
(viii) Incubate the closed tubes floating in the heated water bath for 12 min. 
(ix) Remove tubes and let them cool at RT for 1 h. 
(x) For absorbance measurements, transfer 250 µl of each solution in triplicates into a 96-well 
plate and measure the optical absorbance at 570 nm with a photo-spectrometer (plate reader). 
(xi) Calculate the average absorbance of the triplicate measurements and draw a linear 
regression line from the values obtained from the gelatin dilution series, plotting absorbance against 
relative gelatin concentration (from 0% for blank to 100% for non-diluted gelatin). The absorbance 
at 570 nm corresponds to the concentration of free amine groups; any reduction in free amine 
concentration is assumed to be due to methacryloyl-functionalization. The absorbance of each 
GelMA sample corresponds to a gelatin concentration of X% on the standard curve; the DoF is then 
calculated as DoF = (100 – X)%. 
 
(B) Fluoraldehyde assay to determine the DoF 
(i) Dissolve 0.5 mg/ml of GelMA in PBS and prepare gelatin solutions in PBS to draw a 
standard curve (0.02, 0.1, 0.5, and 1.0 mg/ml). Warm GelMA and gelatin samples to 50 °C and mix 
them until they turn homogenous and transparent. Allow all the solutions to cool to RT. 
(ii) Warm the fluoraldehyde reagent solution to RT before usage. 
(iii) Mix 300 µl of each of the GelMA and gelatin solutions with 600 µl of the fluoraldehyde 
reagent solution in separate test tubes; also prepare a sample containing 300 µl of PBS and 600 µl 
of the fluoraldehyde reagent solution as a control. Mix thoroughly all samples for 1 min to ensure 
completion of the reaction. 
(iv) Pipette 250 µl of each solution in triplicates into a 96-well plate and determine the 
fluorescence intensity at 450 nm using an excitation wavelength of 360 nm. 
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▲ CRITICAL STEP For optimal results, measure the fluorescence intensity of the samples within 
3 min at the same time interval after mixing. Use opaque 96-well plates designed for fluorescence 
assays only. 
(v) Take the average fluorescence intensity and subtract the fluorescence intensity of the PBS 
control from the sample and standard solutions to determine the net fluorescence. Prepare a linear 
calibration curve based on the standard solutions. Determine the fluorescence intensity of the 
GelMA sample corresponding to a gelatin concentration of X mg/ml on the calibration curve and 
the residual amine concentration. The DoF is then calculated as DoF = (0.5 – X) / 0.5 × 100%. 
 
Preparation of GelMA precursor solution  TIMING 1–2 h 
▲ CRITICAL Perform this preparation 1 day prior to cell encapsulation 
▲ CRITICAL For cell culture applications, treat GelMA and GelMA solutions as sterile: work in 
a class II biological safety cabinet and use sealed vessels to transport GelMA-containing solutions. 
Clean all working surfaces with 70% (vol/vol) ethanol before commencing any procedure. 
▲ CRITICAL Use a positive displacement pipette for a viscous GelMA preparation that has a 
concentration higher than 5% (wt/vol). 
14| Prepare at least 10 ml of fresh photo-initiator stock solution by weighing in ≥ 25 mg IC2959 
in a 50-ml centrifuge tube and add PBS to a final concentration of 2.5 mg/ml. Dissolve IC2959 by 
placing the centrifuge tube in a water bath heated to 70 °C for 5–10 min, or until fully dissolved. 
Let solution cool to RT, transfer it to a class II biological safety cabinet and sterilize it using 0.2-μm 
syringe filter units. The stock concentration of IC2959 can be increased depending on the final 
concentration needed in step 17. 
15| Determine the mass of GelMA required (mGelMA) for your application based on the desired 
final concentration (cGelMA) and volume (VGelMA) using the equation mGelMA = cGelMA × VGelMA, and 
allow for ≥ 30% excess to account for losses during hydrogel preparation and to facilitate ease of 
pipetting. Note that VGelMA is dependent on the nominal volume of your casting mould. For 
example, the nominal volume of each of the four recesses of the mould used in this protocol is 
400 μl (50 mm x 4 mm x 2 mm; see Supplementary Figures for mould and cutting guide design) 
which produces a total of 12 hydrogel constructs after cutting (step 25). To prepare 24 hydrogel 
constructs, two recesses of the mould need to be filled completely with hydrogel precursor solution 
(step 23) which requires the preparation of VGelMA ≥ 1,040 μl (two recesses × 400 μl × 130%). 
▲ CRITICAL STEP The minimum total volume of the GelMA hydrogel precursor solution 
(VGelMA) per hydrogel preparation should be ≥ 1 ml to facilitate ease of pipetting and mixing. 
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16| Weigh in the required amount of lyophilized GelMA and add PBS to 4/5 of the total final 
volume to obtain 1.25x the final desired concentration; for example, prepare a 12.5% (wt/vol) 
solution of GelMA if you desire a final GelMA concentration of 10% (wt/vol). 
▲ CRITICAL STEP If other functionalized (methacryloyl-substituted) ECM components, such as 
HAMA, are to be co-polymerized in the hydrogel matrix, they may be dissolved in this mixture at 
1.25x the desired final concentration (if present in solid or lyophilized form). Alternatively, a 
concentrated stock solution of the component may be prepared in PBS and added to the mixture to 
obtain 1.25x the desired final concentration. Take care to adjust the volume of PBS to be added to 
the lyophilized GelMA accordingly, so that all functionalized components are present at 1.25x the 
final concentration after this step. 
17| Add the IC2959 stock solution prepared in step 14 to a final concentration of 0.05% 
(wt/vol), in 1/5 of the total reaction mixture volume (see also step 16). Optionally, the final 
concentration of IC2959 can be varied to 0.5% (wt/vol) as desired, which will have an influence on 
the crosslinking kinetics and mechanical properties but not on cell viability. For recommended 
IC2959 concentrations refer to Table 1. 
18| Allow the GelMA/IC2959 mixture to soak into the solvent protected from light at 4 °C 
overnight. 
▲ CRITICAL STEP GelMA foam needs to be fully immersed into the solvent to enable the 
complete hydration of GelMA. 
 
Cell encapsulation and hydrogel construct preparation  TIMING 3–5 h 
19| Sterilize the Teflon casting mould, acrylic hydrogel cutting guides and glass slides by 
spraying them with 70% (vol/vol) ethanol in a class II biological safety cabinet. 
▲ CRITICAL STEP Ensure equipment has fully dried before usage. 
20| Transfer the tube containing the soaked GelMA foam with IC2959 to a water bath or cell 
culture incubator at 37 °C and allow GelMA to fully dissolve over ~ 3 h or until the mixture turns 
clear. Place tube on a shaker/rocker or manually agitate solution occasionally to accelerate the 
dissolution of GelMA. 
? TROUBLESHOOTING 
21| When GelMA is fully dissolved and the Teflon casting mould, cutting guides and glass 
slides have dried entirely, detach the cells of choice, e.g.: OV-MZ-6, chondrocytes, ECFCs, or 
MSCs following your laboratory’s standard protocol, wash cell pellet with PBS to remove traces of 
trypsin or versene, resuspend the pellet in a suitable volume of medium (5 ml or 10 ml), and 
determine the cell concentration (csuspension) using a hemocytometer or cell counter. 
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22| Determine the required cell number (ncells) based on the desired final cell concentration 
(ccells) and the total volume of GelMA precursor solution prepared in steps 14–18 (VGelMA) using the 
equation ncells = ccells × VGelMA. Take the volume (Vcells) containing ncells from the cell suspension 
prepared in step 21 corresponding to Vcells = ncells / csuspension and transfer to a fresh 50-ml tube. Pellet 
the cells by centrifugation and discard the supernatant. 
▲ CRITICAL STEP The cell concentration (ccells) is dependent on the cell type and specific 
application, and needs to be optimized for cell types not listed in this protocol. For recommended 
cell concentrations refer to Table 1. 
▲ CRITICAL STEP If appropriate for the experiment, also prepare controls containing no cells, 
adding media only. 
23| Wet the pipette tip and carefully aspirate the warm hydrogel precursor solution prepared in 
step 18 with a pipette, by immersing its tip to a depth of 2–5 mm from the solution surface. 
Resuspend the cell pellet in the hydrogel precursor solution at the desired cell concentration by 
carefully pipetting up and down repeatedly, leaving some cell suspension in the tube at all times to 
avoid introduction of air bubbles. Remove existent air bubbles from the cell suspension by 
centrifugation at 200 g for 30 s and reheat suspension to 37 °C, if necessary. Once the cell pellet is 
dislodged and the suspension appears homogeneous and free of air bubbles, transfer the cell 
suspension into the Teflon casting mould using 10% volume excess over the nominal volume of the 
casting mould (here: 440 μl per recess). Cover with a glass slide in a single movement. 
▲ CRITICAL STEP Avoid introducing air bubbles, as entrapped oxygen inhibits radical 
polymerization of the hydrogel precursor solution and leads to incomplete crosslinking. 
? TROUBLESHOOTING 
24| Photo-crosslink cell–hydrogel precursor solution in a UV crosslinker at 365 nm for 10–
15 min, depending on cell type and required hydrogel mechanical properties (see Table 1). UV 
exposure time can be significantly reduced to 30–60 s if a higher concentration of IC2959 is used, 
such as 0.5% (wt/vol), depending on required hydrogel mechanical properties. 
? TROUBLESHOOTING 
25| Remove the crosslinked cell–hydrogel constructs from the Teflon mould by carefully lifting 
the glass slide, and cut the hydrogel strip(s) thus obtained into smaller units using a cutting guide 
and sterile scalpel. 
26| Transfer individual cell-laden hydrogel constructs into a suitable cell culture medium 
(dependent on cell type, see Reagent setup) in a multi-well plate (Figure 2) and maintain in a cell 
culture incubator at 37 °C. If you wish to perform mechanical testing of GelMA proceed to step 27; 
some commonly used cell analysis techniques are described from step 37 onward. 
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▲ CRITICAL STEP If IC2959 concentrations above 0.05% (wt/vol) were used for photo-
crosslinking, replace the cell culture medium three times at 30 min intervals to remove traces of the 
photo-initiator. 
? TROUBLESHOOTING 
 
Mechanical testing of GelMA-based hydrogels  TIMING 1–3 h 
27| Take cell-laden hydrogels prepared as described in steps 19–26 and/or cell-free hydrogels 
(without the inclusion of cells) and incubate them in a suitable buffer, such as PBS or cell culture 
medium, at 37 °C overnight to allow for swelling equilibration or culture cell-laden hydrogels for a 
desired period of time. 
▲ CRITICAL Implementing step 28, and those steps that follow it in the present procedure, 
compromise sterility of the tested hydrogel constructs, so this procedure must be performed as an 
endpoint analysis. 
28| Determine the hydrogel cross-sectional area by direct measurement of hydrogel spatial 
dimensions (option A) or indirectly by measurement of the hydrogel wet weight and height (option 
B). Both options are equally valid and interchangeable for the measurement of the compressive 
moduli of GelMA-based hydrogel cultures by using unconfined compression tests. 
 
(A) Direct determination of hydrogel cross-sectional area 
(i) Use a (digital) caliper to measure the hydrogel’s length and width (rectangular hydrogel 
constructs) or diameter (cylindrical hydrogel constructs) and calculate the cross-sectional area. 
 
(B) Indirect determination of hydrogel cross-sectional area 
(i) Remove excess buffer by carefully blotting the equilibrated hydrogel against a laboratory 
wipe, and determine the hydrogel’s wet weight using an analytical balance. Calculate the cross-
sectional area using the equation A = m / (p × h), in which A is the hydrogel cross-sectional area 
(cm2), m is the hydrogel wet weight (g), ρ is the hydrogel density in g/cm3, and h is the hydrogel 
height in (cm); hydrogel height will be assessed in step 35. 
▲ CRITICAL STEP This method is commonly used, in particular for soft and odd shaped 
hydrogels that deform strongly when applying a caliber, but the hydrogel density needs to be 
measured separately. For 5% (wt/vol) and 10% (wt/vol) GelMA-based hydrogels, the density is 
approximately 1.03 and 1.05 g/cm3, respectively. 
 
29|  Prepare mechanical testing equipment and the hydrogel immersion bath. Equip a vertically 
configured mechanical testing system (e.g. an Instron MicroTester 5848) with a non-porous 
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indenter and a suitable load cell (e.g. 5 N-load cell) and follow the manufacturer’s load cell 
calibration and general user instructions. The cross-sectional area of the intender must be larger 
than that of the hydrogel. 
30| For immersed unconfined compression tests, prepare a suitable hydrogel immersion bath 
with a flat-bottom surface that allows heating to 37 °C by filling with buffer as appropriate. 
31| Determine the contact point of the indenter with the bottom surface of the immersion 
bath and set this position as zero gauge length (position 0 mm). 
32| After the zero gauge length has been reset to the bottom level of the immersion bath in 
step 31, raise the indenter well above the expected hydrogel height. 
33| Place the hydrogel in the immersion bath underneath the indenter. 
? TROUBLESHOOTING 
34| Using a ramp displacement command, lower the indenter at a rate of 0.01 mm/s, until a 
compressive strain of ≥ 15% of the hydrogel height is reached, and record the force-displacement 
data. 
▲ CRITICAL STEP Initiate the linear displacement well above the hydrogel (e.g. 0.3 mm above 
the contact point) to allow for accurate determination of the hydrogel height and compressive strain. 
▲ CRITICAL STEP Ensure hydrogel surfaces are flat and parallel to the bottom of the immersion 
bath. 
▲ CRITICAL STEP For some applications including engineering of load-bearing tissues, which 
undergo large amounts of physical deformation like articular cartilage, the ultimate strength of 
hydrogel constructs may be of interest. To determine the fracture stress and strain, compress the 
sample until it breaks and obtain the stress (Pa) and strain (%) values from the stress-strain curve at 
the point of failure. 
35| Determine the hydrogel height from the force-displacement curve, as the point where the 
force starts deviating significantly from zero. 
36| Determine the compressive modulus Ec (Pa) as the slope of the linear region of the stress-
strain curve between 10 and 15% (wt/vol) hydrogel compressive strain using a linear regression 
analysis or the formula Ec = (σ2 – σ1) / (ε2 – ε1), where σ2 is the stress at ε2, σ1 is the stress recorded 
at force (N) divided by cross-sectional hydrogel area (m2) at ε1, ε2 is a strain of 0.15, and ε1 is a 
strain of 0.10. 
? TROUBLESHOOTING 
 
Brightfield microscopy and CLSM  TIMING 3–5 h 
37| If you wish to visualize the cell morphology and viability of cell-laden GelMA-based 
hydrogels, perform one of the following microscopic procedures10,37. Collect one cell-laden 
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hydrogel after days 1, 7 and 14 of 3D culture (or any other desired time point) for each replicate 
experiment. Perform microscopy of cell-laden GelMA-based hydrogels according to option A, if a 
low contrast image is sufficient (Figure 2), or option B, if a live–dead assessment is desired (Figure 
4), or option C, if a high contrast image is required (Figure 2), or perform all determinations in 
sequence during the same experiment using the same cell-laden GelMA-based hydrogel sample (if 
all microscopy assays are being performed, they must be performed in the order stated here). 
 
(A) Brightfield microscopy 
▲ CRITICAL Don’t open the lid of your ongoing sterile hydrogel culture 24-well plate; tape lid to 
the plate when taking out of the cell culture incubator. 
(i) To visualize the cell morphology of encapsulated cells grown within hydrogels in a 24-well 
plate, take brightfield images of the hydrogel samples using a standard microscope with a 10/20x 
air objective. 
 
(B) CLSM of live hydrogel samples using live–dead staining 
▲ CRITICAL Perform fluorescent staining of live and PFA-fixed samples protected from light. 
(i) Wash hydrogel samples in an individual well of a 24-well plate in 1 ml of PBS for 5 min in 
a cell culture incubator at 37 °C. 
(ii) Incubate samples from step 37A (i) in 0.5 ml of PBS containing FDA 2 µg/ml to stain living 
cells for 15 min at 37 °C. 
(iii) Wash samples with PBS for 5 min at 37 °C as described in step 37B (i). 
(iv) Incubate samples in 0.5 ml PBS containing PI 20 µg/ml to stain dead cells for 15 min at 
37 °C. Alternatively, instead of being subjected to two sequential incubations, hydrogel samples can 
be incubated in PBS containing both FDA and PI for 15 min at 37 °C using the same concentration 
as reported above. 
(v) Image samples with a standard fluorescent microscope with a 10/20x air objective or CLSM 
with a 10/20x oil objective. Please note that at this point, hydrogel samples may be discarded. 
Alternatively, fix, permeabilize and immunofluorescently stain as described in steps 37C (i–vii) 
prior to performing CLSM on PFA-fixed hydrogel samples. Performing option C is appropriate if 
you require a high contrast image of 3D-cultured cells. 
 
(C) CLSM of PFA-fixed hydrogel samples 
(i) Perform fixation and permeabilization of samples with 4% (wt/vol) PFA dissolved in PBS 
and 0.2% (vol/vol) Triton X-100 in PBS into a 24-well plate on a shaker/rocker for 30 min at RT. 
PAUSE POINT Samples can be stored in 4% (wt/vol) PFA in PBS at 4 °C for up to 1 month. 
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(ii) When ready to proceed with the fluorescent staining, permeabilize samples in 0.2% (vol/vol) 
Triton X-100 in PBS for 30 min at RT. 
(iii) Wash samples with 1 ml of glycine 0.1 M in PBS, then twice with 1 ml of PBS for 5 min 
each at RT in an individual well of a 24-well plate. 
(iv) Incubate samples in rhodamine 415–conjugated phalloidin 0.3 U/ml diluted in 1% (wt/vol) 
BSA in PBS for 1 h at RT to stain F-actin. 
(v) Wash samples twice with 1 ml of PBS for 5 min each at RT in an individual well of a 24-
well plate. 
(vi) Incubate hydrogels in DAPI 2.5 µg/ml in PBS for 40–50 min at RT to stain cell nuclei. 
(vii) Wash samples twice with PBS for 5 min each at RT as described in step 37C (v). 
(viii) Image samples with a 10/20x oil objective at three (or more) different positions and acquire 
z-stacks with a constant thickness of 2 μm, reconstructing a cross-section profile of 100–150 
equidistant XY-scans, which will cover a distance of 200–300 μm and spheroids of 50–300 μm 
diameter, using a confocal microscope and generate maximal projections of each image23. If 
required, larger z-stacks (4 µm slice thickness) can also be acquired for bigger spheroids with a 
diameter > 500 µm to cover the complete thickness of the hydrogel. 
 
Cell viability and proliferation assays  TIMING 3–4 days 
38| If you wish to perform cell viability and proliferation assays, collect cell-laden hydrogels 
after days 1, 7 and 14 of 3D culture in triplicates in biological replicate experiments23. Optionally, 
depending on the cell type, hydrogel cultures can be set up for additional time points after days 4 
and 11 of 3D culture or for long-term cultures up to 4 weeks23. If required, quintuplicates can be 
measured per time point and replicate experiment. Set up cell-free hydrogels to obtain the baseline 
fluorescent signal for each culture medium depending on the cell type and time point. 
39| Determine cell viability in the cell-laden GelMA-based hydrogel sample, option A, or cell 
proliferation in the same sample, option B, or perform option A followed by option B during the 
same experiment (the assays must be performed in this order). 
 
(A) AlamarBlue® cell viability assay 
(i) Culture each individual cell-laden GelMA-based hydrogel in an individual well of a 24-well 
plate for the desired period of time, for example 2–4 weeks as mentioned in step 38, in a cell culture 
incubator at 37 °C. 
(ii) Prepare a fresh, sterile 24-well plate with at least 0.5 ml of the specific culture medium for the 
cell type listed in the reagent setup containing 4% (vol/vol) AlamarBlue® reagent and place each 
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hydrogel replicate into individual wells 6 h prior to each time point and incubate in a cell culture 
incubator at 37 °C. Alternatively, 48-well plates can be used. 
(iii) After 6 h, transfer individual hydrogels into an individual well of a new 24-well plate in 1 ml of 
PBS per well on a shaker/rocker for 30 min to destain the AlamarBlue® reagent-colored hydrogels 
(blue or pink) and measure fluorescent signals of the AlamarBlue® reagent-containing medium in 
triplicates into a black 96-well plate using a fluorescent plate reader. 
(iv) Transfer each individual destained hydrogel to a 2-ml conical tube using a spatula and freeze at 
–80 °C for at least 48 h if you plan to also perform option B. 
     PAUSE POINT Samples can be stored at –80 °C for at least 1 month. 
 
(B) CyQuant® cell proliferation assay 
(i) Implement step 39A (i) of the present procedure as described above. Alternatively, if 
AlamarBlue® cell viability assay has already been performed, thaw hydrogel samples or set aside at 
step 39A (iv). 
(ii) Incubate cell-laden GelMA-based hydrogel samples with 300 µl of proteinase K solution 
(0.5 mg/ml in PBE buffer) in 2-ml conical tubes overnight for at least 16 h at 65 °C using a heat 
block. 
▲ CRITICAL STEP The optimal digestion temperature for proteinase K is 65 °C. Make sure that 
the temperature is kept constant over the incubation time for optimal hydrogel degradation. 
(iii) Centrifuge samples at 8,000 g for 30 s at RT and pipette 50 µl of each hydrogel replicate in 
triplicates into a black 96-well plate. 
(iv) Prepare a DNA standard curve using the λDNA standard provided with the CyQuant® assay kit 
over eight concentrations ranging from 0 to 2,000 ng/ml in 1x cell lysis buffer, and pipette 50 µl of 
each DNA standard concentration in triplicates into a black 96-well plate. 
▲ CRITICAL STEP If more than one black 96-well plate is needed, it is recommended to prepare 
a DNA standard curve for each individual plate. 
(v) Add 50 µl of RNase A solution to each well (containing samples and DNA standards) to 
degrade any RNA reassuring DNA specificity and incubate for 1 h at RT on a shaker/rocker. 
(vi) Add 100 µl of CyQuant® GR dye solution to each well and incubate for 5 min at RT on a 
shaker/rocker before measuring the fluorescent signals using a fluorescent plate reader. 
▲ CRITICAL STEP Ensure that the CyQuant® GR dye solution is added in a light-protected 
room and incubated protected from light to ensure the integrity of the fluorescent signals. 
(vii) Overlay the standard curve with a linear regression line and determine the DNA content of 
individual samples. 
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▲ CRITICAL STEP Subtract the fluorescent signal from the cell-free hydrogel sample for each 
cell type and time point measured. 
▲ CRITICAL STEP If the fluorescent signal of the sample with the highest cell number exceeds 
the fluorescent signal of the DNA standard with the highest concentration, repeat the assay by 
diluting all cell-containing samples with 1x cell lysis buffer 1:5–1:10. 
 
Total RNA extraction from GelMA-based hydrogels  TIMING 2–4 h 
▲ CRITICAL RNA is sensitive to degradation by ubiquitous RNases and precautions need to be 
taken if working with RNA. If possible, perform RNA isolation in a designated area and treat bench 
and equipment surfaces with commercially available RNase-inactivating agents, for example an 
RNase decontamination solution. Clean benches with 100% (vol/vol) ethanol. Change gloves 
regularly and do not touch surfaces and equipment to avoid reintroducing RNases. Always use 
certified RNase-free disposable plastic ware, including filtered pipette tips and conical 
microcentrifuge tubes, and designated RNase-free reagents. Avoid cross-contamination between 
samples. 
▲ CRITICAL It may be necessary to pool multiple cell-laden hydrogels, if cells were cultured at 
densities below 1.0 × 105 cells/ml in the GelMA precursor solution. 
40| Culture cell-laden GelMA-based hydrogels for a desired period of time, for example 2–4 weeks 
as mentioned in steps 37 and 38, in a cell culture incubator at 37 °C. 
41| Proceed with RNA extraction implementing the directions in option A, if extracting RNA 
from samples with relatively high cell numbers (> 1.0 × 106 cells per individual or pooled hydrogel 
sample) or option B, which is optimal for low cell numbers (< 1.0 × 105 cells per individual or 
pooled hydrogel sample)13,23. 
 
(A) Total RNA extraction using TRIzol® reagent 
(i) Transfer each individual hydrogel to a 2-ml conical tube with 1 ml of TRIzol® reagent using a 
spatula. If possible, disrupt hydrogels by pipetting up and down several times. Incubate at RT for 
5 min while gently shaking occasionally. 
(ii) Snap-freeze samples in liquid nitrogen (freezing facilitates the homogenization of hydrogels in 
the following step) and store at –80 °C until further usage. 
     PAUSE POINT Samples can be stored at –80 °C for at least 1 month. 
(iii) Thaw samples at RT and homogenize hydrogels either manually, by carefully passing 
hydrogels through a 19-gauge needle with a 5-ml syringe 15–20 times or until hydrogels are 
completely homogenized, or mechanically, by adding five borosilicate beads or three stainless steel 
beads to each sample and homogenizing the resulting mixtures in a Bullet Blender tissue 
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homogenizer, Mini-Beadbeater, TissueLyser LT, or a similar mechanical tissue homogenizer. 
Proceed by spinning twice for 1 min or 2–5 min at 50 Hz or until hydrogels are completely 
homogenized. While manual homogenization is suitable for rather soft hydrogels (< 50 kPa), 
mechanical disruption using a tissue homogenizer needs to be used for stiff hydrogels (> 50 kPa). 
▲ CRITICAL STEP When implementing manual homogenization, hydrogel pieces may clog the 
needle occasionally. Take care to avoid spillage and contamination when clearing clogged needles 
by gentle pressure. 
▲ CRITICAL STEP Ensure best possible sample homogenization to maximize cell disruption and 
RNA yield. 
(iv) Proceed to phase separation following the TRIzol® reagent manufacturer’s instructions for 
the isolation and purification of total RNA using a chloroform and 2-propanol precipitation. 
▲ CRITICAL STEP Ensure RNA integrity by agarose gel analysis or using a bioanalyzer and 
probe for absence of contaminants using a nanodrop photo-spectrometer (make sure that 
A260nm/280nm ratio is over 1.8 and A260nm/230nm ratio is in the 2.0–2.2 range) before proceeding to 
downstream applications, such as reverse transcription to cDNA. If necessary, perform additional 
RNA clean-up using commercial column-based RNA purification kits. 
 
(B) Total RNA extraction using RNeasy Micro Kit 
(i) Transfer hydrogels into 0.35 ml of RLT buffer containing 1% (vol/vol) β-mercaptoethanol in 2-
ml tubes using a spatula. If possible, disrupt hydrogels by pipetting up and down several times. 
(ii) Snap-freeze samples in liquid nitrogen (freezing facilitates the homogenization of hydrogels 
in the following step) and store at –80 °C until further usage. 
     PAUSE POINT Samples can be stored at –80 °C for at least 1 month. 
(iii) Thaw samples at RT and homogenize hydrogels either manually, as described in step 41A (iii), 
or mechanically, by loading the lysate onto a QIAshredder spin column placed in a 2-ml conical 
tube and centrifugation at 12,500 g for 2 min at RT using a standard bench top centrifuge. 
▲ CRITICAL STEP Ensure best possible sample homogenization to maximize cell disruption and 
RNA yield. 
(iv) Proceed following the RNeasy Micro Kit manufacturer’s instructions for the isolation and 
purification of total RNA. 
 
 TIMING 
Steps 1–11, GelMA functionalization, dialysis and lyophilization: 1–2 weeks 
Steps 12–13, Characterization of GelMA functionalization: 1–2 h 
Steps 14–18, Preparation of GelMA precursor solution: 1–2 h 
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Steps 19–26, Cell encapsulation and hydrogel construct preparation: 3–5 h 
Steps 27–36, Mechanical testing of GelMA-based hydrogels: 1–3 h 
Step 37, Brightfield microscopy and CLSM: 3–5 h 
Steps 38–39, Cell viability and proliferation assays: 3–4 days 
Steps 40–41, Total RNA extraction from GelMA-based hydrogels: 2–4 h 
 
? TROUBLESHOOTING 
Troubleshooting advice can be found in Table 2. 
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TABLE 1 │ Recommended parameters for 3D cell cultures in high DoF GelMA. For enhanced 
chondrogenic differentiation, 9.5% (wt/vol) GelMA and 0.5% (wt/vol) HAMA can be used, instead 
of the 10% (wt/vol) GelMA reported in the Table48. 
Cell type Cell 
density 
(cells/ml) 
GelMA 
concentration 
[% (wt/vol)] 
IC2959 
concentration 
[% (wt/vol)] 
UV 
exposure 
time (min) 
UV 
intensity 
(mW/cm2) 
Expected 
compressive 
modulus (kPa) 
Reference(s) 
OV-MZ-6 2.8 × 105 5 0.05 10 2.7 3.2–5.2 37 
Chondrocytes 1.0 × 107 10 0.05 15 2.6 25–30 10,48 
ECFCs 1.0 × 106 5 0.5 0.33 6.7 4–5 40 
MSCs 1.0 × 106 5 0.5 0.33 6.7 4–5 40 
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TABLE 2 │ Troubleshooting table 
Step Problem Possible reason Solution 
3 Stirring not possible Stir bar too small and/or 
reaction volume too large  
Use a larger stir bar or an 
overhead stirrer with propeller 
agitator or reduce reaction 
volume 
  Gelatin not dissolved Fully dissolve gelatin at 50 °C 
 Phase separation occurs Insufficient stirring and/or 
mixing 
Increase stirring speed and use 
a larger stir bar, or use an 
overhead stirrer with propeller 
agitator 
4 Ineffective separation Thermal gelation occurred Maintain GelMA solution at 
37–50 °C and use a 
temperature-controlled 
centrifuge (if possible) 
6 Solution is cloudy  Incomplete dialysis  Extend dialysis with daily 
water changes until the 
solution turns clear 
 Solids are present Incomplete removal of 
methacrylic anhydride 
and/or acid 
Remaining solids can be 
removed by filtration (step 8) 
  Spontaneous crosslinking Maintain GelMA solutions in 
the dark and remove solids by 
filtration (step 8) 
7 pH > 7.4 Too much NaHCO3 was 
added 
Reduce pH with HCl 0.1 M or 
1 M 
8 Filter units clog Unsuitable filter 
membrane 
Use filter units with PES 
membrane, such as Nalgene™ 
Rapid-Flow™ sterile disposable 
filter units 
  Thermal gelation occurred Maintain GelMA solution at 
37–50 °C 
20 GelMA does not dissolve GelMA has crosslinked Maintain GelMA solutions in 
the dark during and after 
functionalization, and store the 
lyophilized GelMA protected 
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from light and moisture at –
20 °C 
23 Air bubbles in GelMA–
cell suspension 
Volume too small and/or 
unsuitable pipette 
Increase excess volume and/or 
use positive displacement 
pipettes; air bubbles can be 
removed by short 
centrifugation (at 200 g for 
~ 30 s); re-heat suspension to 
37 °C and mix carefully before 
transferring into the casting 
mould 
24 GelMA is not forming 
covalent hydrogels 
Functionalization 
unsuccessful 
Follow functionalization 
protocol and determine the 
degree of functionalization 
before cell-encapsulation 
  Problems with photo-
initiator 
Always prepare and use a fresh 
photo-initiator solution 
  UV polymerization 
parameters incorrect 
Ensure a wavelength of 
365 nm for photo-crosslinking 
and aim for a consistent UV 
dosage 
  The casting mould used is 
oxygen-permeable 
Use casting moulds made from 
non-permeable materials, such 
as Teflon 
26 Hydrogels stick to glass 
slide 
Glass slide was treated or 
coated 
Use non-treated or 
hydrophobic glass slides; 
release sticking hydrogels 
using a sterile scalpel by gently 
pressing the blade flat against 
the glass slide and carefully 
sliding underneath the 
hydrogel to lift it off 
33 Hydrogel does not remain 
underneath indenter 
Too much buffer or 
hydrogel unconfined 
Remove excess buffer until 
hydrogel is just covered by it; 
it may help to confine the 
hydrogel loosely with, for 
example, a large stainless steel 
washer 
36 Inconsistent results Hydrogel surfaces not flat Ensure hydrogels are flat by 
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between technical 
replicates 
or aligned in a parallel 
fashion 
using a suitable casting mould 
  Air bubbles trapped inside 
hydrogels 
Avoid introducing air bubbles 
during cell encapsulation 
 
Anticipated results 
This protocol can be used for a variety of applications in cancer research, as well as tissue 
engineering and regenerative medicine. This modular technology platform provides a universal and 
easily adaptable 3D cell culture system that combines natural binding sites with controllable 
properties. All components of GelMA-based hydrogels are affordable, broadly available and easy to 
handle, whereas the chemical modification enables researchers to control reproducibility, physico-
chemical and mechanical properties, and cellular behavior. Additionally, GelMA-based hydrogel 
constructs can be molded into wide-ranging shapes and are easy to produce, which has proven to be 
a great advantage over systems like Matrigel and collagen type I gels, and allows for a greater 
variety of experimental procedures and analysis. 
Following the GelMA functionalization procedure described herein, by using the recommended 
0.6 g of methacrylic anhydride per 1 g of dissolved gelatine, an estimated DoF of 80% can be 
achieved. An estimated DoF of 50% is the least in order to generate 5% (wt/vol) GelMA-based 
hydrogels. The mechanical properties of GelMA-based hydrogels are largely dependent on the DoF, 
polymer and photo-initiator concentrations, thermal gelation state of the GelMA precursor solution, 
as well as the UV exposure (intensity and time) during photo-crosslinking of the polymer 
network39. As hydrogel stiffness and crosslinking density are directly related to and strongly 
influence cellular behavior, mechanical characterization represents a cost- and time-effective 
measure of reproducibility between different GelMA batches and hydrogel preparations. 
Furthermore, it can also be performed to assess changes in the physical properties of the hydrogels 
following ECM deposition or enzymatic degradation during 3D cell culture and tissue engineering 
experiments. The practically achievable range of stiffness is approximately 1–200 kPa39. 
Although various 3D matrices are increasingly employed for cell-based studies, there are 
difficulties in adapting routinely used cytological methodologies to 3D cellular microenvironments. 
No consideration is given to the different cell architecture, cell surface area exposed or interference 
of the 3D matrix. Our team has optimized the application of two quantitative assays to 3D cell 
cultures in which cells are embedded within different hydrogel materials13,23. Cell viability and 
proliferation of 3D-cultured cells can be determined performing the AlamarBlue® and CyQuant® 
assays, respectively. Although the AlamarBlue® reagent enables researchers to measure a cell’s 
metabolic activity, results of the CyQuant® assay provide indication of cell proliferation, based on 
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the DNA content of the cell-containing sample. Both procedures can be performed individually and 
independently from each other using the same cell-laden GelMA-based hydrogel sample. 
Both total RNA extraction procedures, TRIzol® reagent or a RNeasy Micro Kit, can be employed to 
isolate high quality total RNA from cells encapsulated in GelMA-based hydrogels for a variety of 
downstream applications, including reverse transcription real-time PCR, (micro)array analysis, 
whole transcriptome analysis using next generation sequencing, digital PCR, northern analysis and 
cDNA library constructions. 
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FIGURES 
 
Figure 1 │ Overview of the GelMA-based hydrogel preparation protocol. GelMA is dissolved in 
PBS at 37 °C and mixed with the photo-initiator to obtain the precursor solution. Cells, and 
optionally hyaluronic acid methacrylate (HAMA; indicated by a dashed line), are added to the 
precursor solution before casting it into a custom-made Teflon mould. The casting mould is then 
covered with glass slides and transferred into a UV crosslinker to enable formation of the hydrogel 
by photo-polymerization. Using a custom-made cutting guide, the hydrogel stripes thus obtained are 
cut into constructs of equal size (4 mm x 4 mm x 2 mm) and can be used for biological assays and 
as a cell delivery vehicle for animal studies. 
 
Figure 2 │ GelMA-based hydrogel preparation and 3D cell culture. The custom-made and 
sterilized Teflon mould is filled with cell-laden precursor solution under sterile conditions and 
covered with glass slides. After UV-initiated crosslinking, a custom-made cutting guide is required 
to cut the hydrogel strip into equal squares (4 mm x 4 mm x 2 mm), which are then transferred into 
culture medium to enable cell growth and spheroid formation. Brightfield microscopy indicates the 
appearance of spheroids after 14 days of 3D culture of ovarian cancer OV-MZ-6 cells, which can be 
visualized by CLSM and maximal projections depicting cell nuclei (DAPI, blue) and F-actin 
(rhodamine 415–conjugated phalloidin, red). 
 
Figure 3 │ Application of GelMA-based hydrogels as cell delivery vehicles for an intraperitoneal 
animal model. A. Ovarian cancer OV-MZ-6 cells were transfected with a luciferase vector23 and 
encapsulated within GelMA-based hydrogels [5% (wt/vol) polymer concentration]. After 2 weeks 
of 3D cell culture, bioluminescent signals (3.15 × 105 ± 9.32 × 104 photons/s/cm2/steradian; n = 12) 
of cell-laden GelMA-based hydrogels were confirmed prior to intraperitoneal implantation into 
NOD-scid mice. B. Bioluminescent imaging confirmed tumor growth 8 weeks after implantation 
(1.80 × 106 ± 1.70 × 106 photons/s/cm2/steradian; n = 6), and ex vivo bioluminescent imaging of the 
peritoneal organs indicated tumor spread. Human-derived tumor load was immunohistochemically 
detected by positive nuclear mitotic apparatus protein 1 (NuMA; Epitomics, cat. no. s2825, 1:100 
dilution) staining as shown by representative images from two different mice per group. C. 4 weeks 
post implantation, mice were treated with intraperitoneal paclitaxel injections (10 mg/kg, 
twice/week) over 4 weeks, leading to a decreased tumor load, as detected by bioluminescent 
imaging (6.59 × 105 ± 1.01 × 106 photons/s/cm2/steradian; n = 6). The effect of paclitaxel was also 
confirmed via ex vivo bioluminescent imaging, with only minor tumor spread within the 
peritoneum. Smaller tumors were formed upon paclitaxel treatment as indicated by NuMA staining. 
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D. The average radiance indicated a paclitaxel response of 63% (n = 6). All animal experiments 
conformed to Queensland University of Technology animal ethics approval. 
 
Figure 4 │ Application of GelMA-based hydrogels as breast cancer bone colonization animal 
model. A. Metastatic breast cancer MDA-MB-231BO (MDA-BO) and MDA-MB-231 (MDA) cells 
and non-tumorigenic epithelial MCF10A cells were encapsulated within GelMA-based hydrogels 
[5% (wt/vol) polymer concentration]. After 1 week of 3D cell culture, cell viability was assessed by 
CLSM by live/dead staining (FDA, green/PI, red). After 2 weeks of 3D cell culture, cell 
proliferation was measured with an Alamar Blue® assay (mean ± standard error; n = 5). B. Melt 
electrospun scaffolds seeded with primary human osteoblastic cells were cultured over 8 weeks in 
vitro before subcutaneous implantation together with recombinant human bone morphogenetic 
protein 7 into NOD-scid mice. After 8 weeks of ectopic bone formation in the humanized tissue-
engineered bone, cell-laden hydrogels were implanted in close proximity to mimic invasion of the 
humanized bone by human breast cancer cells. Development of breast tumors in contact with the 
engineered bone was observed macroscopically (explant images) and microscopically [hematoxylin 
and eosin (H&E) staining] for both metastatic groups, but not for the control group. Human tumor 
and bone cells were detected immunohistochemically by positive NuMA (Epitomics, cat. no. s2825, 
1:100 dilution) staining, as shown by representative images from each group. All animal 
experiments conformed to Queensland University of Technology animal ethics approval. NB, new 
bone; T, tumor; BM, bone marrow; CT, connective tissue; AT, adipose tissue; BV, blood vessel; 
hTEBC, humanized tissue-engineered bone. 
 
Figure 5 │ Formation of a humanized vascular network in GelMA-based hydrogels. A. Human 
ECFCs and MSCs were co-cultured within GelMA-based hydrogels [5% (wt/vol) polymer 
concentration; DoF: 50%] at a 1:1 ratio, as indicated by CLSM images of DsRed-ECFCs (left) and 
CMFDA-MSCs (right) after 6 days of co-culture. B. DsRed-ECFCs were imaged in the complete 
hydrogel construct by CLSM, and a 2D projection (XY-plane) was collected along the Z-axis (left). 
A 3D reconstruction with a cross-section covering a thickness of 400 μm in the direction of the 
white arrow was acquired (right). C. MSCs differentiated into perivascular cells surrounding the 
ECFC capillaries (left). A CLSM image shows the spatial distribution of the DsRed-ECFC-lined 
capillaries surrounded by alpha smooth muscle actin-expressing (αSMA; Abcam, cat. no. ab9465, 
clone EA-53,1:200 dilution; anti-mouse Alexa Fluor® 488, Life Technologies, cat. no. A-11001, 
1:1,000 dilution) MSCs (right, top). The zoom-in view depicts details of a capillary and a cross-
section image taken in the direction of the yellow arrow (right, bottom). D. CLSM image showing 
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that lumens were lined exclusively by DsRed-ECFC and surrounded by αSMA-expressing MSCs 
(yellow arrowhead); adapted from40. 
 
Figure 6 │ Microfluidic channels coated with GelMA-based hydrogels for utilization of a 
cardiomyocyte culture model. A. Representation of the coating procedure, with cross-sections of a 
single microfluidic channel perpendicular to the direction of the flow (top) and channel cross-
sections along the direction of the flow (bottom). GelMA prepolymer [5% (wt/vol) polymer 
concentration; DoF: ~ 80%] is perfused through the microfluidic channel and exposed to UV-
initiated crosslinking. Non-crosslinked prepolymer is then washed away with PBS. The channel can 
be subsequently seeded with cells and perfused with culture medium. PDMS, polydimethylsiloxane 
B. CLSM images of cardiomyocytes stained for F-actin (rhodamine 415–conjugated phalloidin, 
red) and cell nuclei (DAPI, blue) show an elongated morphology and alignment with the GelMA-
coated microchannel on day 6 after seeding. C. CLSM images show immunostaining of 
cardiomyocyte markers troponin I (red, top; Abcam, cat. no. ab10231, clone 4C2, 1:200 dilution; 
anti-mouse Alexa Fluor® 594, Life Technologies, cat. no. A-11005, 1:1,000 dilution), αSMA (green; 
Abcam, cat. no. ab9465, clone EA-53, 1:200 dilution; anti-mouse Alexa Fluor® 488, Life 
Technologies, cat. no. A-11001, 1:1,000 dilution) and connexin-43 (red, bottom; Abcam, cat. no. 
ab11370, 1:200 dilution; anti-rabbit Alexa Fluor® 594, Life Technologies, cat. no. A-11012, 
1:1,000 dilution) inside the GelMA-coated microchannel, with cell nuclei counterstaining (DAPI, 
blue); adapted from44. Scale bars, 50 μm. 
 
Figure 7 │ Effect of Teflon casting mould depth on mechanical and swelling properties of GelMA-
based hydrogels. GelMA was dissolved to a final concentration of 10% (wt/vol) in PBS and photo-
crosslinked in the presence of 0.05% (wt/vol) Irgacure 2959 by 15 min exposure to 365 nm light at 
an intensity of 2.6 mW/cm2 in a CL-1000 crosslinker (UVP). A. Compressive moduli of cell-free 
GelMA-based hydrogels prepared in Teflon moulds with either 1 mm or 2 mm depth were 
determined after incubation in PBS at 37 °C overnight (mean ± standard error; n = 6) and differ 
significantly (p<0.001). B. Effective hydrogel swelling was determined by weighing GelMA-based 
hydrogels immediately after crosslinking and again after swelling in PBS at 37 °C overnight and 
changes significantly (p<0.001) with the casting mould depth. The difference of wet weights was 
expressed as percentage (mean ± standard error; n = 6). 
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SUPPLEMENTARY INFORMATION 
 
Supplementary Figure 1 │ Hydrogel casting mould. 
Technical drawing and dimensions for the custom-made Teflon casting mould. This mould 
produces hydrogel strips of 50 mm x 4 mm x 2 mm (length x width x height), which can be cut into 
smaller units using a cutting guide. All dimensions are in mm. 
 
Supplementary Figure 2 │ Hydrogel cutting guide. 
Technical drawing and dimensions for the custom-made Teflon cutting guide. This guide can be 
used to cut hydrogel strips obtained after polymerization in the Teflon casting mould into smaller 
units of 4 mm x 4 mm x 2 mm (length x width x height). All dimensions are in mm. 
